Description :

A portion of the medicines in patients who have been treated for disease may make lasting damage the heart. Because of chemotherapy or radiation, cardiovascular intricacies, for example, premature blockage of arteries of heart, heart rhythm disorders and cardiovascular breakdown may develop. Chemotherapeutic heart lethality is for the most part characterized into 2 kinds: Type 1 chemotherapy-related left ventricular (LV) systolic dysfunction and Type 2 chemotherapy-mediated cardiotoxicity.

Related Cardio Oncology Conference | Cardio Oncology Conference 2020 | Cardio Oncology Meetings | Cardio Oncology Meetings 2020 | Cardio Oncology Congress | Cardio Oncology Congress 2020 | Cardio Oncology Events | Cardio Oncology Events 2020

12th German Kardiodiagnostik Day 2020, Leipzig , Germany, American Society of Echocardiography 33rd Annual State-of-The-Art Echocardiography 2020, Scottsdale , United States, Mayo Clinic Annual Cardiology at Cancun: Topics In Cardiology 2020, Cancun , Mexico

Related Associations: Cardiovascular Credentialing International (CCI), American Society of Hypertension (ASH),American Society of Nuclear Cardiology (ASNC), International Society for Heart Research (ISHR), American Association of Heart Failure Nurses (AAHFN), International Academy of Cardiology (IAC)

  • Radiation-Induced Heart Disease
  • Targeting Tyrosine Kinases for Cancer Therapy
  • Novel Targeted Therapies
  • Cardio-oncology programs
  • Platinum-Based Chemotherapy Agents
  • Chemotherapy-related cardiac dysfunctions